Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Palmer, Stephen John"'
Autor:
Palmer, Stephen John, Murphy, Peter James, Dias, Sofia, Glynn, David, Hodgson, Robert, Beresford, Lucy
Background The first histology-independent marketing authorisation in Europe was granted in 2019. This is the first time a cancer treatment has been approved based on a common biomarker rather than the location in the body where the tumour originated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::2dbf69b2e6408e58390e0652063ef0c2
https://eprints.whiterose.ac.uk/178458/1/Histology_independent_HTA_final_report_Acccepted_version_.docx
https://eprints.whiterose.ac.uk/178458/1/Histology_independent_HTA_final_report_Acccepted_version_.docx
Autor:
Corbett, Mark Stephen, Duarte, Ana Isabel, Llewellyn, Alexis, Altunkaya, James, Harden, Melissa, Harris, Martine, Walker, Simon Mark, Palmer, Stephen John, Dias, Sofia, Soares, Marta O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::9e222d6540d85a3bdec8a701ea1e2702
https://eprints.whiterose.ac.uk/165238/1/3033614.pdf
https://eprints.whiterose.ac.uk/165238/1/3033614.pdf
Autor:
Cox, Edward Miles, Wade, Rosalind Fay, Peron, Mathilde Michelle Germaine, Dietz, Kristina Charlotte, Eastwood, Alison Jane, Palmer, Stephen John, Griffin, Susan
The National Institute for Health and Care Excellence (NICE) invited Pfizer, the manufacturer of inotuzumab ozogamacin (henceforth inotuzumab), to submit clinical and cost-effectiveness evidence for inotuzumab, as part of NICE’s Single Technology A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::fb922894ab836afc56ab5471cc444886
https://eprints.whiterose.ac.uk/147007/1/Revised_Inotuzumab_Review_01.02.2019.docx
https://eprints.whiterose.ac.uk/147007/1/Revised_Inotuzumab_Review_01.02.2019.docx
Autor:
Saramago Goncalves, Pedro Rafael, Yang, Huiqin, Llewellyn, Alexis, Palmer, Stephen John, Simmonds, Mark Crawford, Griffin, Susan
OBJECTIVE: To evaluate the cost-effectiveness of high-throughput, non-invasive prenatal testing (HT-NIPT) for fetal RhD genotype to guide antenatal prophylaxis with anti-D immunoglobulin compared to routine antenatal anti-D immunoglobulin prophylaxis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::417308ede257ebc182030a83d4962324
https://eprints.whiterose.ac.uk/127348/1/NIPT_CE_main_ReRevision_012018_final.docx
https://eprints.whiterose.ac.uk/127348/1/NIPT_CE_main_ReRevision_012018_final.docx
Autor:
Sideris, Eleftherios, Corbett, Mark Stephen, Palmer, Stephen John, Woolacott, Nerys Frances, Bojke, Laura
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::e6a5a5351e44a9abf69d211f2174fcaa
https://eprints.whiterose.ac.uk/102301/1/Apremilast_Pharmacoeconomics_paper_17052016_clean.docx
https://eprints.whiterose.ac.uk/102301/1/Apremilast_Pharmacoeconomics_paper_17052016_clean.docx
Autor:
Neves De Faria, Rita Isabel, Walker, Simon Mark, Whyte, Sophie, Dixon, Simon, Palmer, Stephen John, Sculpher, Mark John
Cost-effective interventions are often implemented slowly and sub-optimally in clinical practice. In such situations, a range of implementation activities may be considered to increase uptake. A framework is proposed to use cost-effectiveness analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::bff761b2e02e65c2b05b0ce3a5181c90
https://eprints.whiterose.ac.uk/99275/1/Accepted_paper.docx
https://eprints.whiterose.ac.uk/99275/1/Accepted_paper.docx
Autor:
Walker, Simon Mark, Asaria, Miqdad, Manca, Andrea, Palmer, Stephen John, Gale, Christopher, Shah, Anoop D, Abrams, Keith, Crowther, Michael, Timmis, Adam, Hemingway, Harry, Sculpher, Mark
Aims To examine long term health care utilisation and costs of patients with stable coronary artery disease (SCAD). Methods and results Linked cohort study of 94,966 patients with SCAD in England, 1st January 2001 to 31st March 2010, identified from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::4b213a3153e6e27f8b000a260c4499d4
https://eprints.whiterose.ac.uk/96845/1/ehjqcco.qcw003.full_1_.pdf
https://eprints.whiterose.ac.uk/96845/1/ehjqcco.qcw003.full_1_.pdf
Autor:
Asaria, Miqdad, Walker, Simon Mark, Palmer, Stephen John, Gale, Christopher, Shah, Anoop D, Abrams, Keith, Crowther, Michael, Manca, Andrea, Timmis, Adam, Hemingway, Harry, Sculpher, Mark
OBJECTIVES: To use electronic health records (EHR) to predict lifetime costs and health outcomes of patients with stable coronary artery disease (stable-CAD) stratified by their risk of future cardiovascular events, and to evaluate the cost-effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a91151ddc6cfda55ecc09d6f39e5706e
https://eprints.whiterose.ac.uk/95319/1/Heart_2016_Asaria_heartjnl_2015_308850.pdf
https://eprints.whiterose.ac.uk/95319/1/Heart_2016_Asaria_heartjnl_2015_308850.pdf